AU2006243065B2 - Enzyme inhibitors - Google Patents

Enzyme inhibitors Download PDF

Info

Publication number
AU2006243065B2
AU2006243065B2 AU2006243065A AU2006243065A AU2006243065B2 AU 2006243065 B2 AU2006243065 B2 AU 2006243065B2 AU 2006243065 A AU2006243065 A AU 2006243065A AU 2006243065 A AU2006243065 A AU 2006243065A AU 2006243065 B2 AU2006243065 B2 AU 2006243065B2
Authority
AU
Australia
Prior art keywords
compound
stage
phenyl
optionally substituted
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006243065A
Other languages
English (en)
Other versions
AU2006243065A1 (en
Inventor
Kenneth William John Baker
Alan Hornsby Davidson
Stephen John Davies
Alistair David Graham Donald
Alan Hastings Drummond
Francesca Ann Mazzei
David Festus Charles Moffat
Sanjay Ratilal Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of AU2006243065A1 publication Critical patent/AU2006243065A1/en
Application granted granted Critical
Publication of AU2006243065B2 publication Critical patent/AU2006243065B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2006243065A 2005-05-05 2006-05-04 Enzyme inhibitors Ceased AU2006243065B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0509223.4 2005-05-05
GB0509223A GB0509223D0 (en) 2005-05-05 2005-05-05 Enzyme inhibitors
PCT/GB2006/001605 WO2006117549A1 (en) 2005-05-05 2006-05-04 Enzyme inhibitors

Publications (2)

Publication Number Publication Date
AU2006243065A1 AU2006243065A1 (en) 2006-11-09
AU2006243065B2 true AU2006243065B2 (en) 2012-05-03

Family

ID=34685155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006243065A Ceased AU2006243065B2 (en) 2005-05-05 2006-05-04 Enzyme inhibitors

Country Status (19)

Country Link
US (3) US7939666B2 (enExample)
EP (2) EP2301939A1 (enExample)
JP (1) JP5405820B2 (enExample)
KR (1) KR101307815B1 (enExample)
CN (1) CN101133060B (enExample)
AT (1) ATE512150T1 (enExample)
AU (1) AU2006243065B2 (enExample)
BR (1) BRPI0607410A2 (enExample)
CA (1) CA2599411C (enExample)
DK (1) DK1879895T3 (enExample)
ES (1) ES2367369T3 (enExample)
GB (1) GB0509223D0 (enExample)
IL (1) IL185580A (enExample)
MX (1) MX2007010456A (enExample)
NZ (1) NZ560289A (enExample)
PL (1) PL1879895T3 (enExample)
PT (1) PT1879895E (enExample)
WO (1) WO2006117549A1 (enExample)
ZA (1) ZA200707091B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP3530290A1 (en) * 2005-05-05 2019-08-28 GlaxoSmithKline Intellectual Property Development Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
GB0509223D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
BRPI0622100A2 (pt) 2006-10-30 2011-12-27 Chroma Therapeutics Ltd hidroxamatos como inibidores de desacetilase de histona
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
CA2768466C (en) * 2009-07-22 2018-08-14 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
CA2784600A1 (en) 2009-12-21 2011-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) New inhibitors of cyclophilins and uses thereof
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
ES2402252B1 (es) * 2011-09-26 2014-03-10 Universidad De Granada Compuesto con actividad antileishmania
KR20130047623A (ko) * 2011-10-28 2013-05-08 주식회사종근당 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 하이드록사메이트 유도체 및 이를 포함하는 약제학적 조성물
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
RS59458B1 (sr) 2012-10-17 2019-11-29 Macrophage Pharma Ltd N-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alanin i njegov tetrabutil ester
CN103172540B (zh) * 2013-03-18 2015-07-01 潍坊博创国际生物医药研究院 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
SG11201706146UA (en) 2015-02-02 2017-08-30 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10961219B2 (en) * 2016-03-22 2021-03-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derivatives and their use as selective inhibitors of caspase-2
WO2017216297A1 (en) 2016-06-16 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Dosage regimen
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
TWI650139B (zh) * 2017-10-11 2019-02-11 行政院原子能委員會核能硏究所 含有放射性同位素氟的異羥肟酸類造影劑、其製備方法及其用途
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ｐｔｐ－１ｂ阻害剤およびその用途
CN111393404B (zh) * 2019-01-02 2023-02-17 中国科学院上海药物研究所 一类苯并噻吩类化合物及其药物组合物及应用
CN113121527B (zh) * 2019-12-31 2024-09-06 上海辉启生物医药科技有限公司 三环类化合物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1099355B (it) 1978-10-12 1985-09-18 Sclavo Inst Sieroterapeut Composizione adatta alla determinazione in cinetica del glucosio
JPS6188884A (ja) * 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1264860B1 (it) * 1993-06-21 1996-10-17 Guidotti & C Spa Labor Derivati di acidi cis- e trans-2(((2-(isdrossiammino)-2-ossoetil)- alchilammino)carbonil)cicloesancarbossilici
US6204293B1 (en) * 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
AU4249700A (en) * 1999-04-19 2000-11-02 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative
TR200201052T2 (tr) 1999-09-08 2003-01-21 Sloan-Kettering Institute For Cancer Research Yeni hücre farklılaştırıcı ajanlar sınıfı ve hıstone deacetylase inhibitörleri, ve burada kullanım yöntemleri
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
GB0003476D0 (en) 2000-02-16 2000-04-05 British Biotech Pharm Acetal Hydroxylamine compounds
DE60143520D1 (de) 2000-03-24 2011-01-05 Methylgene Inc Inhibitoren der histon-deacetylase
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
DE60115279T2 (de) 2000-09-29 2006-12-28 Topotarget Uk Ltd., Abingdon Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
AR035513A1 (es) * 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
CA2434601A1 (en) 2001-01-12 2002-09-12 Methylgene, Inc. Methods for specifically inhibiting histone deacetylase-4
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
EP1472216A2 (en) * 2002-02-07 2004-11-03 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
ATE425152T1 (de) 2002-03-13 2009-03-15 Janssen Pharmaceutica Nv Aminocarbonylderivate als histone-deacetylase- inhibitoren
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
HRP20040801A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Sulfonylamino derivatives as novel inhibitors of histone deacetylase
EP1485348B1 (en) 2002-03-13 2008-06-11 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
NZ536116A (en) 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
BR0313371A (pt) 2002-08-02 2005-07-05 Argenta Discovery Ltd Composto, uso de um composto e método de tratamento de doença
US7221775B2 (en) 2002-11-12 2007-05-22 Intellivid Corporation Method and apparatus for computerized image background analysis
SI1611088T1 (sl) 2003-04-07 2009-12-31 Pharmacyclics Inc Hidroksamati kot terapevtska sredstva
WO2004110989A1 (en) 2003-05-14 2004-12-23 Bayer Pharmaceuticals Corporation N-hydroxy-7-(arylamino)heptanamide derivatives useful for treating hyper-proliferative disorders
EP1633751A1 (en) * 2003-06-16 2006-03-15 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
WO2005007091A2 (en) 2003-07-07 2005-01-27 Georgetown University Histone deacetylase inhibitors and methods of use thereof
EP1663201A4 (en) 2003-07-15 2009-10-28 Korea Res Inst Of Bioscience USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
JP2007501775A (ja) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
MXPA05011286A (es) 2003-08-20 2006-01-24 Axys Pharm Inc Derivados de acetileno como inhibidores de histona deacetilasa.
RU2356547C2 (ru) 2003-08-26 2009-05-27 Мерк ЭйчДиЭйСи Рисерч ЛЛС Способы лечения рака с использованием ингибиторов hdac
PT1673349E (pt) 2003-09-22 2010-09-28 S Bio Pte Ltd Derivados benzimidazole: preparação e aplicações farmacêuticas
US7868205B2 (en) 2003-09-24 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CA2542096A1 (en) * 2003-10-09 2005-04-21 Aton Pharma, Inc. Thiophene and benzothiophene hydroxamic acid derivatives
EP1677785A1 (en) * 2003-10-22 2006-07-12 Arpida A/S Benzimidazole derivatives and use thereof as peptide deformylase inhibitors
GB0509223D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
EP3530290A1 (en) 2005-05-05 2019-08-28 GlaxoSmithKline Intellectual Property Development Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase

Also Published As

Publication number Publication date
PL1879895T3 (pl) 2011-11-30
MX2007010456A (es) 2007-10-11
JP2008540389A (ja) 2008-11-20
EP1879895A1 (en) 2008-01-23
US9133104B2 (en) 2015-09-15
CA2599411A1 (en) 2006-11-09
JP5405820B2 (ja) 2014-02-05
BRPI0607410A2 (pt) 2009-09-01
KR101307815B1 (ko) 2013-09-12
IL185580A0 (en) 2008-01-06
US20140163042A1 (en) 2014-06-12
US20130116318A1 (en) 2013-05-09
DK1879895T3 (da) 2011-09-19
US8686032B2 (en) 2014-04-01
US20090291978A1 (en) 2009-11-26
EP1879895B1 (en) 2011-06-08
EP2301939A1 (en) 2011-03-30
PT1879895E (pt) 2011-09-06
NZ560289A (en) 2010-11-26
US7939666B2 (en) 2011-05-10
ATE512150T1 (de) 2011-06-15
CN101133060B (zh) 2013-06-05
GB0509223D0 (en) 2005-06-15
ZA200707091B (en) 2008-10-29
ES2367369T3 (es) 2011-11-02
AU2006243065A1 (en) 2006-11-09
CA2599411C (en) 2013-12-03
CN101133060A (zh) 2008-02-27
KR20080015388A (ko) 2008-02-19
IL185580A (en) 2012-08-30
WO2006117549A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
AU2006243065B2 (en) Enzyme inhibitors
CN101528677B (zh) Hdac抑制剂
US7973181B2 (en) Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity
WO2004113336A1 (en) Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
CN101553475B (zh) 作为组蛋白脱乙酰基酶抑制剂的异羟肟酸
US20140155439A1 (en) Enzyme inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired